An imaging agent reveals aggregated tau protein in the brain during PET scans and could improve the diagnosis of neurodegenerative diseases, particularly tauopathies.

Recent data show that the drug bamlanivimab, also known as LY-CoV555, does not appear to help those with severe cases of COVID-19, but trials continue for milder cases.

Government leaders claim the reductions are necessary to free up assets to deal with COVID-19 and address corruption in research.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

The President was hospitalized on Friday evening and has been receiving an aggressive treatment of experimental and standard drugs.

The AIDS activist, also known as the Berlin patient, represented optimism that scientists could find a way to beat HIV.

The changes, which affect the declarations authors have to sign and the peer-review process, have received a mixed response from the scientific community.

Eli Lilly reports a 72 percent reduction in hospitalization risk among patients who received its monoclonal antibody compared to those who received a placebo.

A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.